DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Xylocaine (Lidocaine Hydrochloride) - Indications and Dosage



Xylocaine administered intravenously is specifically indicated in the acute management of ventricular arrhythmias such as those occurring in relation to acute myocardial infarction, or during cardiac manipulation, such as cardiac surgery.



Single Direct Intravenous Injection (bolus)

The usual dose is 50 to 100 mg of lidocaine hydrochloride (0.7 to 1.4 mg/kg; 0.32 to 0.63 mg/lb) administered intravenously under ECG monitoring.  This dose may be administered at the rate of approximately 25 to 50 mg/min (0.35 to 0.7 mg/kg/min; 0.16 to 0.32 mg/lb/min).  Sufficient time should be allowed to enable a slow circulation to carry the drug to the site of action.  If the initial injection of 50 to 100 mg does not produce a desired response, a second dose may be injected after 5 minutes.  NO MORE THAN 200 TO 300 mg OF LIDOCAINE HYDROCHLORIDE SHOULD BE ADMINISTERED DURING A ONE HOUR PERIOD.

Continuous Intravenous Infusion

Following bolus administration, intravenous infusions of Xylocaine may be initiated at the rate of 1 to 4 mg/min of lidocaine hydrochloride (0.014 to 0.057 mg/kg/min; 0.006 to 0.026 mg/lb/min).  The rate of intravenous infusions should be reassessed as soon as the patient’s basic cardiac rhythm appears to be stable or at the earliest signs of toxicity.  It should rarely be necessary to continue intravenous infusions of lidocaine for prolonged periods.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit.  Do not use if solution is discolored or cloudy.


Controlled clinical studies in the pediatric population to establish dosing schedules have not been conducted.


In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.


For direct intravenous injection, Xylocaine (lidocaine HCl Injection, USP) without preservatives is supplied in the following dosage form:

Product No.
 NDC No.
 491889  63323-498-89  20 mg/mL
 5 mL ampules packaged in tens.

Solution should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

XYLOCAINE is a trademark of APP Pharmaceuticals, LLC.

Manufactured for:

Made in Austria


Revised: May 2011

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017